Adverum Biotechnologies Inc (ADVM)
7.53
+0.25
(+3.43%)
USD |
NASDAQ |
Oct 04, 16:00
7.545
+0.02
(+0.20%)
After-Hours: 20:00
Adverum Biotechnologies Shareholders Equity (Annual): 83.47M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 83.47M |
| December 31, 2022 | 181.52M |
| December 31, 2021 | 316.18M |
| December 31, 2020 | 434.35M |
| December 31, 2019 | 174.96M |
| December 31, 2018 | 201.17M |
| Date | Value |
|---|---|
| December 31, 2017 | 184.03M |
| December 31, 2016 | 215.60M |
| December 31, 2015 | 252.59M |
| December 31, 2014 | 149.48M |
| December 31, 2013 | -0.218M |
| December 31, 2012 | -0.997M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
83.47M
Minimum
2023
434.35M
Maximum
2020
238.10M
Average
181.52M
Median
2022
Shareholders Equity (Annual) Benchmarks
| EyePoint Pharmaceuticals Inc | 266.32M |
| Cassava Sciences Inc | 137.47M |
| Regenxbio Inc | 311.74M |
| Editas Medicine Inc | 349.10M |
| Apellis Pharmaceuticals Inc | 194.52M |